Treatment of attention deficit hyperactivity disorder with neurotherapy.
Significant public health concerns exist regarding our current level of success in treating ADHD. Medication management is very helpful in 60-70% of patients. Side effects, lack of compliance and the fact that stimulant medications cannot be given late in the day limit the benefits largely to school hours. While stimulants improve behavior and attention, less of an effect has been noted on academic and social performance. Continuing concerns exist about long-term safety, and studies on long-term cardiovascular and neurophysiological effects have not been carried out. Neurotherapy for ADHD offers an effective alternate for patients whose treatment is limited by side effects, poor medication response and in cases in which the patients and/or their parents refuse to consider medications. Studies indicate clinical improvement is largely related to measurable improvements in the EEG signature, evidenced by declining theta/beta ratios over frontal/central cortex and/or reduced theta/alpha band amplitudes.
Nash
J K
JK
Behavioral Medicine Associates, Inc., MN 55434, USA.
D000124:Achievement; D000513:Alpha Rhythm; D001288:Attention / Q000187:drug effects; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy / Q000628:therapy*; D001519:Behavior / Q000187:drug effects; D001611:Beta Rhythm; D001676:Biofeedback, Psychology / Q000379:methods*; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000627:therapeutic use; D003216:Conditioning, Operant; D004569:Electroencephalography; D006801:Humans; D011634:Public Health; D012919:Social Behavior; D013826:Theta Rhythm
D000697:Central Nervous System Stimulants